Dr. Wang is an established and well known expert in cardiovascular research and the industry. Dr. Wang’ has major contributions to both pharmacology and device therapies for cardiovascular diseases. He was the pioneer to introduce biotechnology and biopharmaceuticals into China, funded and led two companies to manufacture recombinant protein drugs and interventional cardiology devices.He has both clinical degree (MM, Hebei Medical College) and research degree (Ph.D, physiology, New York Medical College). He completed fellowship training at Duke and Harvard University.
Dr. Wang has served as a consultant to a number of the world’s largest pharmaceutical companies, venture capital firms, start-up companies and consulting firms. He has been working with Dr. Levin and Mr. Gelfand together as a team for more than 15 years, guided key animal experiments and first-in-man studies to prove the concept of Ardian’s renal denervation therapy for hypertension, heart failure and other cardiovascular diseases.